What anti-aging treatments improve skin quality in individuals with Classical Ehlers-Danlos Syndrome (EDS), Ehlers-Danlos Syndrome (EDS), or Joint Hypermobile (JHS) syndromes?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 13, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

For individuals with Classical Ehlers-Danlos Syndrome (EDS), EDS, or Joint Hypermobility Syndromes, the most effective anti-aging treatment to improve skin quality is the use of autologous platelet concentrates, such as platelet-rich fibrin (PRF), which has been deemed extremely effective in minimizing further facial aging and potentially reversing it. This approach is supported by a recent study published in 2025 1, which highlights the importance of addressing the underlying causes of facial aging, including deep fat atrophy and vascular degeneration.

The signs of aging in individuals with EDS or Joint Hypermobility Syndromes can be particularly pronounced due to impaired regeneration capacity and natural barrier function of the skin. Key areas of concern include:

  • Periorbital and perioral regions, which are more frequently clinically related to visible signs of aging
  • Deep fat atrophy, primarily caused by a decrease in age-related blood flow
  • Vascular degeneration, considered a major cause of the initiation of facial aging

Given the fragile skin associated with EDS conditions, it is essential to prioritize gentle, non-invasive approaches. Some additional considerations include:

  • Topical retinoids at low concentrations (0.025-0.05%) to support collagen production
  • Vitamin C serums (10-15% L-ascorbic acid) for antioxidant protection and collagen support
  • Hyaluronic acid moisturizers to hydrate the skin without causing excessive stretching
  • Sun protection with broad-spectrum SPF 30+ daily
  • Peptide-based products as gentler alternatives to more aggressive treatments

However, autologous platelet concentrates, such as PRF, offer a more targeted approach to addressing the underlying causes of facial aging, making it a preferred treatment option for individuals with Classical EDS, EDS, or Joint Hypermobility Syndromes 1. As always, consultation with a dermatologist familiar with connective tissue disorders is crucial to determine the best course of treatment.

From the Research

Anti-Aging Treatments for Classical EDS, EDS, or Joint Hyper mobility syndromes

There are no specific studies that directly address anti-aging treatments for improving skin quality in individuals with Classical EDS, EDS, or Joint Hyper mobility syndromes. However, the following information can be gathered from the available studies:

  • The skin is one of the most commonly affected body parts in heritable connective tissue disorders, such as Ehlers-Danlos Syndrome (EDS) 2.
  • EDS is characterized by joint hypermobility, skin hyperextensibility, and tissue fragility 3.
  • The hypermobile type of EDS (hEDS) involves generalized joint hypermobility, musculoskeletal manifestations, and mild skin involvement along with the presence of several comorbid conditions 3.
  • Management principles for EDS and joint hypermobility syndrome include a multidisciplinary approach, covering pharmacologic, physical and occupational therapy, surgical, and nutriceutical aspects, as well as general lifestyle recommendations 2.
  • There is no specific mention of anti-aging treatments in the provided studies, but it can be inferred that a comprehensive management plan may include measures to improve skin quality and reduce the risk of skin-related complications.

Key Considerations

  • Individuals with EDS or joint hypermobility syndrome may require specialized care and management to address their unique needs and symptoms 2, 4, 5, 3, 6.
  • A thorough assessment and diagnosis are crucial to develop an effective treatment plan 2, 4, 5, 3, 6.
  • Further research is needed to understand the complex phenotypes and genetic basis of EDS and joint hypermobility syndrome, which may lead to the development of targeted treatments and therapies 3.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Joint hypermobility syndrome (a.k.a. Ehlers-Danlos Syndrome, Hypermobility Type): an updated critique.

Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia, 2013

Research

Hypermobile Ehlers-Danlos syndromes: Complex phenotypes, challenging diagnoses, and poorly understood causes.

Developmental dynamics : an official publication of the American Association of Anatomists, 2021

Research

A framework for the classification of joint hypermobility and related conditions.

American journal of medical genetics. Part C, Seminars in medical genetics, 2017

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.